Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
By modeling a <i>TP53</i> mutation in mice that has relatively weak cancer penetrance, this study provides <i>in vivo</i> evidence that the human R337H mutation can compromise p53 activity and promote tumorigenesis.<b>Significance:</b> A germline mutation in the oligomerization domain of p53 decreases its transactivation potential and renders mice susceptible to carcinogen-induced liver tumorigenesis.<i>Cancer Res; 78(18); 5375-83.©2018 AACR</i>.
|
30042151 |
2018 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our results suggest that MDM2 SNP 309 may contribute to the LFL phenotype and also to an earlier age at diagnosis of ACC and BC cancer in carriers of the R337H founder mutation.
|
28756477 |
2018 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In southern Brazil, pediatric adrenocortical tumor is a sentinel cancer for detecting families with germline p.R337H mutation in TP53 gene.
|
28864397 |
2018 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
TP53 R337H carriers have a lifelong predisposition to cancer with a bimodal age distribution: 1 peak, represented by ACT, occurs in the first decade of life, and another peak of diverse cancer types occurs in the fifth decade.
|
28387921 |
2017 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A detailed statistical analysis of 171,500 DNA tests in Brazilian neonates found that 0.27% of the general population is positive for this mutation, and some of the estimated 200,000 Brazilian R337H carriers in southern and southeastern Brazil have already developed cancer.
|
25736369 |
2015 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
R337H mutation of the TP53 gene as a clinical marker in cancer patients: a systematic review of literature.
|
26681051 |
2015 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have assessed the prevalence of p.R337H in two groups: (1) 59 BC affected women with a familial history (FH) suggestive of hereditary cancer syndrome but no LFS/LFL features; (2) 815 BC affected women unselected for cancer FH, diagnosed with BC at or before age 45 or at age 55 or older.
|
24936644 |
2014 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with the homozygous TP53 p.R337H genotype will require careful surveillance for lifetime cancer risk and for effects on metabolic capacity later in life.
|
23570263 |
2013 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence of the germline p.R337H mutation and of other germline TP53 mutations was investigated in a general group of children with cancer and exclusively in children fulfilling the clinical criteria for LFS/LFL, respectively.
|
24122735 |
2013 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Childhood adrenocortical tumors (ACT) are rare malignancies, except in southern Brazil, where a higher incidence rate is associated to a high frequency of the founder R337H TP53 mutation.
|
22539591 |
2012 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genomic DNA samples from 493 children with malignancies were screened for the R337H mutation.
|
21192060 |
2011 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
It shows that cancer inheritance can occur in the absence of an obvious germline mutation, calling for caution in assessing early cancers in populations with common founder mutations such as p.R337H in Southern Brazil.
|
22004116 |
2011 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Family history of cancer (with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/14) of them were compatible with Li-Fraumeni-like syndrome.
|
21445348 |
2011 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In Southern Brazil, a recurrent TP53 mutation, p.R337H, is detected in families with cancer predisposition.
|
19877175 |
2010 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Because protocols for cancer-risk management in Li-Fraumeni or related syndromes are debatable, extreme care should prevail in predictive testing of children for R337H.
|
19717094 |
2009 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing of 53 Brazilian subjects with no cancer history showed that R337H was not a common polymorphism in that population.
|
16494995 |
2007 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no association between the presence of germline or tissue R337H p53 mutation and malignancy at diagnosis.
|
15952083 |
2005 |